Beike Biotech Applies for China Use of Stem Cells in Lupus Patients

Beike Biotechnology filed with the CFDA for approval to use human umbilical cord (UC) derived mesenchymal stem cells (MSCs) to treat Systemic Lupus Erythamatosus (SLE). Beike based the request on a single-arm, 40-patient test of the treatment in patients with active, refractory SLE. The UC-derived MSCs were well-tolerated and, according to the company, provided a clinical benefit to the patients. Beike, based in Shenzhen, focuses on stem cell treatments. More details..... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.